1h Free Analyst Time
The primary ciliary dyskinesia market is forecasted to grow by USD 160.2 million during 2023-2028, accelerating at a CAGR of 5.7% during the forecast period. The report on the primary ciliary dyskinesia market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness of PCD conditions, improving healthcare infrastructure, and increase in funding for research activities.
The primary ciliary dyskinesia market is segmented as below:
By Type
- Genetic testing
- Electron microscopy
- Nasal nitric Oxide (NnO) testing
By Application
- Hospitals
- Speciality clinics
- Research centers
By Geographical Landscape
- Europe
- North America
- Asia
- Rest of World (ROW)
The report on the primary ciliary dyskinesia market covers the following areas:
- Primary ciliary dyskinesia market sizing
- Primary ciliary dyskinesia market forecast
- Primary ciliary dyskinesia market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Additional Value/Volume Data
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Application
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global primary ciliary dyskinesia market: Acare Technology Co. Ltd., Amgen Inc., AstraZeneca PLC, Bayer AG, Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CHIESI Farmaceutici SpA, F. Hoffmann La Roche Ltd., Fitwel Pharmaceuticals Pvt. Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Medigene AG, Novartis AG, Pfizer Inc., ReCode Therapeutics, Regeneron Pharmaceuticals Inc., Rotech Healthcare Inc., Sanofi SA, and Teva UK Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing pipeline projects on PCD."
According to the report, one of the major drivers for this market is the increasing awareness of PCD conditions.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acare Technology Co. Ltd.
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Becton Dickinson and Co.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- CHIESI Farmaceutici SpA
- F. Hoffmann La Roche Ltd.
- Fitwel Pharmaceuticals Pvt. Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Medigene AG
- Novartis AG
- Pfizer Inc.
- ReCode Therapeutics
- Regeneron Pharmaceuticals Inc.
- Rotech Healthcare Inc.
- Sanofi SA
- Teva UK Ltd.
